With Vigil, Alector, Denali and Novartis trailblazing in TREM2 approaches for Alzheimer’s Disease, and Roche, Sanofi, Biogen & Novartis pushing ahead for BTKi’s, the neuroinflammation field are eager to unpack new clinical readouts to inform the future of drug development in the CNS.

Refining utility of GFAP and NFL as translatable biomarkers, validating exploratory markers, novel pathways, modalities and targets beyond TREM2 and BTK will be crucial to developing the next generation of neuroinflammatory-targeted therapeutics to target the breadth of immunopathology in Alzheimer’s, Parkinson’s, ALS, MS, Huntington’s, CIDP and many more.

Uniting annually 100+ CNS scientists, directors and lab heads from Alector, Biogen, Eisai, EMD Serono, Merck, Muna, Therapeutics, Novartis, Roche, Sanofi, Takeda, Vigil Neuroscience and many more, the 7th Neuroimmunology Drug Development Summit is biopharma’s must attend forum to learn, benchmark and debate cutting edge mechanistic insights into glial biology, TREM2 and BTKi clinical learnings to optimize neuroimmunology translation and develop transformative therapeutics for neurological disorders.

Event link here.